Key result
Inhibiting exosome release from human CDCs increases in vitro cardiomyocyte apoptosis by ~100% vs control.
Why the study?
It has not yet been demonstrated by a genetic approach that exosome release contributes to the therapeutic effect of transplanted human cardiosphere-derived cells.
Does inhibiting exosome release from human CDCs via nSMase2 knockdown affect proliferation, apoptosis, and migration in cardiomyocytes, fibroblasts, and endothelial cells in vitro?
Does inhibiting exosome release from human CDCs via nSMase2 knockdown affect proliferation, apoptosis, and migration in cardiomyocytes, fibroblasts, and endothelial cells in vitro?
Exosomes secreted by human cardiosphere-derived cells mediate critical paracrine effects that promote angiogenesis, reduce fibroblast proliferation, and protect cardiomyocytes from apoptosis in vitro.
May support exosome-mediated cardiomyocyte protection in vitro; hypothesis-generating for cardiac repair strategies.
Numerous studies have shown a beneficial effect of cardiosphere-derived cell (CDC) therapy on regeneration of injured myocardium. Paracrine signaling by CDC secreted exosomes may contribute to improved cardiac function. However, it has not yet been demonstrated by a genetic approach that exosome release contributes to the therapeutic effect of transplanted CDCs. By employing a lentiviral knockdown (KD) strategy against neutral spingomyelinase 2 (nSMase2), a crucial gene in exosome secretion, we have defined the role of physiologically secreted human CDC-derived exosomes on cardiac fibroblast, endothelial cell and primary cardiomyocyte proliferation, cell death, migration and angiogenesis using a series of in vitro coculture assays. We found that secretion of hCDC-derived exosomes was effectively inhibited by nSMase2 lentiviral KD and shRNAi expression was stable and constitutive. hCDC exosome release contributed to the angiogenic and pro-migratory effects of hCDCs on HUVECs, decreased proliferation of fibroblasts, and decreased apoptosis of cardiomyocytes. These in vitro reactions support a role for exosome secretion as a paracrine mechanism of stem cell-mediated cardiac repair in vivo. Importantly, we have established a novel tool to test constitutive inhibition of exosome secretion in stem cell populations in animal models of cardiac disease.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2016) studied In vitro study of cardiac cells (n=4). Lentiviral knockdown of nSMase2 in human CDCs vs. Scrambled shRNA LV control vector (Scr CDCs) was evaluated on Cardiomyocyte apoptosis (TUNEL-positive nuclei at one week) (p=0.0006). Inhibiting exosome release from human cardiosphere-derived cells via nSMase2 knockdown significantly increased cardiomyocyte apoptosis to 26% compared to 13% with control cells in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: